Advertisement
Advertisement

TCRT

TCRT logo

Alaunos Therapeutics Inc

2.00
USD
-0.07
-3.38%
Dec 18, 13:41 UTC -5
Open

Alaunos Therapeutics Inc Profile

About

Alaunos Therapeutics Inc. is a clinical-stage oncology-focused cell therapy company. It focused on developing T-cell receptor therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform. Alaunos Therapeutics Inc., formerly known as Ziopharm Oncology Inc., is based in HOUSTON.

Info & Links

CEO

Dale Curtis Hogue

Headquarters

2617 BISSONNET ST,SUITE 225
HOUSTON, TX 77005, UNITED STATES

Auditor

RSM US LLP

Share holders

167

Employees

1

Alaunos Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

3.20M

Enterprise Value

1.52M

Enterprise Value/EBITDA(ttm)

-0.13

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.12

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-7056.25%

Return on Equity(ttm)

-267.77%

Return on Invested Capital(ttm)

-230.73%

Return on Assets(ttm)

-209.18%

Income Statement

Revenue(ttm)

6.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

6.00K

EBITDA(ttm)3

-11.76M

Net Income Available to Common(ttm)

-11.78M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

-0.45

52-Week Change

-79.80%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

1.60M

Dividend Yield

0.00%

Float4

1.52M

% Held by Insiders

5.11%

% Held by Institutions

27.72%

Balance Sheet

Total Cash(mrq)

1.68M

Total Cash Per Share(mrq)

1.05

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

4.30%

Quick Ratio(mrq)

4.30%

Book Value Per Share(mrq)

1.70

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.74

Free Cash Flow(ytd)

-4.38M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement